Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1446377 | 0.98 | AKR1C1 (0.42) | AKR1C1PTPN1GSK3BLMNACES2 | |
| SCHEMBL64920 | 0.79 | AKR1C1 (0.44) | AKR1C1LMNACES2CES1TSHR | |
| SCHEMBL29973163 | 0.78 | CES2 (0.52) | CES2CES1TSHRALDH1A1CYP3A4 | |
| SCHEMBL23579244 | 0.78 | CES2 (0.52) | CES2CES1TSHRALDH1A1CYP3A4 | |
| SCHEMBL28139686 | 0.78 | AKR1C1 (0.42) | AKR1C1LMNATSHRHDAC4HPGD | |
| SCHEMBL8529984 | 0.77 | AKR1C1 (0.45) | AKR1C1LMNACES2CES1TSHR | |
| SCHEMBL6692163 | 0.77 | AKR1C1 (0.45) | AKR1C1GSK3BLMNACES2CES1 | |
| SCHEMBL29155399 | 0.77 | AKR1C1 (0.45) | AKR1C1LMNACES2CES1TSHR | |
| SCHEMBL11257983 | 0.76 | LMNA (0.43) | AKR1C1LMNACES2CES1TSHR | |
| SCHEMBL3678905 | 0.76 | OPRM1 (0.33) | HDAC4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119241381-A | Arylcyclohexylamine derivatives and their use in the treatment of psychotic disorders | 吉尔伽美什制药公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-115190815-B | Arylcyclohexylamine derivatives and their use in the treatment of psychotic disorders | 吉尔伽美什制药公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20220409555-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS INC (US) | 2022-12-29 | — | — | US | disclosed |
| EP-4081301-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | Gilgamesh Pharmaceuticals, Inc. (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-115190815-A | Arylcyclohexylamine derivatives and their use in the treatment of psychotic disorders | 吉尔伽美什制药公司 | 2022-10-14 | — | — | CN | disclosed |
| US-11344510-B2 | Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2021134086-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021134086-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| US-9381170-B2 | Cycloalkyl-diamines for neurodegenerative disorders | MediSynergics, LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-20160151308-A1 | Cycloalkyl-Diamines For Neurodegenerative Disorders | MediSynergics, LLC (US) | 2016-06-02 | — | — | US | disclosed |
| EP-2004667-B1 | NOVEL 11 BETA - HYDROXYANDROSTA-4-ENE-3-ONES | SUN PHARMA ADVANCED RES CO LTD (IN) | 2013-09-04 | — | — | EP | disclosed |
| US-20090054388-A1 | NOVEL 11 BETA-HYDROXYANDROSTA-4-ENE-3-ONES | SUN PHARMA ADVANCE RESEARCH COMPANY (IN) | 2009-02-26 | — | — | US | disclosed |
| EP-2004667-A2 | NOVEL 11 BETA - HYDROXYANDROSTA-4-ENE-3-ONES | Sun Pharma Advanced Research Company Limited (IN) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007099548-A2 | NOVEL 11 BETA - HYDROXYANDROSTA-4-ENE-3-ONES | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2007-09-07 | — | — | WO | disclosed |
| US-6083992-A | Use of 2-methylamino-2-phenylcyclohexanone for the treatment of bacterial infections | DETLEF PREISS (DE) | 2000-07-04 | — | — | US | disclosed |
| US-6020381-A | Use of 2-methylamino-2-phenylcyclohexanone for the treatment of protozoan infections | DETLEG PREISS (DE) | 2000-02-01 | — | — | US | disclosed |
| EP-0885869-A1 | THERAPEUTIC AGENT FOR DIABETES | Japan Tobacco Inc. (JP) | 1998-12-23 | — | — | EP | disclosed |
| US-5811464-A | Use of 2-methylamino-2-phenylcyclohexanone for the treatment of bacterial, fungal, virus or protozoan infections as well as for immunomodulation | Preiss, Detlef (DE) | 1998-09-22 | — | — | US | disclosed |
| EP-0672411-B1 | Use of 2-methylamino-2-phenylcyclohexanon for the treatment of infections and as immunomodulator | PREISS DETLEF DR (DE) | 1998-04-29 | — | — | EP | disclosed |
| EP-0672411-A1 | Use of 2-methylamino-2-phenylcyclohexanon for the treatment of infections and as immunomodulator | Preiss, Detlef, Dr. (DE) | 1995-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344510-B2 | Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders | HTR2C, PNMT, HTR2A | AKR1C1 3580/4885PTPN1 3852/4885GSK3B 2648/4885 |
| US-20160151308-A1 | Cycloalkyl-Diamines For Neurodegenerative Disorders | HTT, CLN6, SMN1; SMN2 | AKR1C1 2900/4885PTPN1 4722/4885GSK3B 2855/4885 |
| US-20090054388-A1 | NOVEL 11 BETA-HYDROXYANDROSTA-4-ENE-3-ONES | HSD11B1, HSD3B1, HSD3B2 | AKR1C1 110/4885PTPN1 4712/4885GSK3B 2735/4885 |
| US-20220409555-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | HTR2C, PNMT, HTR2A | AKR1C1 3880/4885PTPN1 3958/4885GSK3B 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.